IMPORTANT! Updated March 15, 2019
In Summary, for those who took the steroids:

Benefits in NNT

  • 100% saw no benefit
  • 0% were helped by preventing post-herpetic neuralgia
  • None were helped (preventing post-herpetic neuralgia)

Harms in NNT

  • 0% were harmed by medication side effects
  • None were harmed (medication side effects)

View As:

Source: He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2008;1:CD005582

Efficacy Endpoints: Incidence of PHN 6 months after zoster diagnosis, pain severity score at 6 months

Harm Endpoints: Serious (life-threatening or requiring prolonged hospital admission) or non-serious medication adverse events

Narrative: Post-herpetic neuralgia (PHN) is a syndrome of continued and chronic pain after the development of shingles, which is a reactivation of the varicella zoster (chickenpox) virus. The likelihood of developing shingles increases with age, with estimates of 10-20% incidence throughout one’s lifetime. The risk of developing post-herpetic neuralgia also increases with age, and is rare in patients under 30. PHN is exquisitely painful and debilitating, and unfortunately few effective treatments exist. It is theorized that treatment with steroids before the PHN develops may reduce the risk of PHN developing.

This Cochrane review concludes that data are clearly lacking. While 787 subjects in 5 trials were deemed sufficient to evaluate this question, only one study (with 34 subjects) compared steroids to placebo. Other studies compared steroids to placebo or no treatment (we assume because there was no possible role for a placebo effect); still other studies compared an anti-viral plus steroids to an anti-viral plus placebo (and evaluated pain scales but not the binary outcome of yes/no PHN). The review, however, does suggest that there may be benefits in terms of pain scales at 6 months after zoster diagnosis , or in certain age subgroups for zoster.

Harms were rare , and were not statistically more common in placebo and steroid arms.

Of note, the classic teaching of “steroids within 48-72 hours of rash development" was not conclusive in any of the high-quality studies chosen for inclusion by the Cochrane Group.

In summary, further research with larger populations is needed to answer this question.

Caveats: As stated above steroids may or may not work to reduce the incidence of post-herpetic neuralgia. The data are inadequate.

Also, as we have seen in other reviews of steroids treatments, there probably are harms with steroid administration (hyperglycemia, transient immunocompromise), but it is unclear how clinically relevant or patient-important these harms are.

Author: Graham Walker, MD

Published/Updated: November 26, 2010

  1. The Title Bar

    The title bar is color-coded with our overall recommendation.

    • Green: Benefits outweigh risks.
    • Yellow: Unclear risk/benefit profile.
    • Red: Benefits do not outweigh risks.
    • Black: Obvious harms, no clear benefits.
  2. Tip content...